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Abstract: 
Objective:  
To expand upon the limited knowledge of the long-term effects of prolonged-released 
(PR)-fampridine in patients with multiple sclerosis (PwMS) regarding safety, walking 
improvements and changes in drug responsiveness. 
Methods:  
Fifty-three PwMS who completed the FAMPKIN core study were included in this 
extension trial. Drug efficacy was assessed in an open-label and randomized double-
blind, placebo-controlled study design with regular baseline assessments over a period 
of 2 years using the Timed 25-Foot Walk (T25FW), 6-Minute Walk Test (6MWT) and 12-
item MS Walking Scale (MSWS-12) as outcome measures. 
Results: 
Data showed good tolerability and persisting efficacy of PR-fampridine during long-term 
treatment in PwMS. Significant improvements in walking speed, endurance and self-
perceived ambulatory function were observed during open-label (T25FW: +11.5%; 
6MWT: 10.7%; MSWS-12: 6.1 points) and double-blind controlled treatment with PR-
fampridine (T25FW: +13.1%; 6MWT: 11.9%; MSWS-12: 7.4 points). Several patients 
showed changes in drug responsiveness over time, resulting in an increased proportion 
of patients exceeding 10% or 20% improvements in walking measures after long-term 
treatment.   
Conclusion:  
Efficacy and tolerability data confirmed PR-fampridine as a valuable long-term treatment 
for improving ambulatory function in gait-impaired PwMS. Similar results in open-label 
and double-blind phases reveal that the walking tests used are objective and reliable. 
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The considerable proportion of patients in whom responsiveness to PR-fampridine 
changed over time emphasizes the importance of regular re-assessment of drug 
efficacy in clinical practice to optimize treatment. Such re-assessments seem to be 
particularly important in patients with poor initial drug responses, as this group 
demonstrated enhanced responsiveness after long-term treatment.   
Classification of evidence:  
This study (NCT01576354) provides Class II evidence that PR-fampridine significantly 
improved gait compared to placebo in a 2 week study in patients with multiple sclerosis 
who had been using PR-fampridine for 2 years. 
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Introduction: 
Multiple sclerosis (MS) is the leading neurological cause of persisting disability in young 
adults.1 
Impaired mobility due to walking deficits occurs in approximately 75% of patients with 
MS (PwMS)2, 3 and is reported by these patients as the single most devastating 
symptom.4, 5  
Fampridine (4-aminopyridine, dalfampridine) is the only approved medication for the 
symptomatic treatment of gait disorders in PwMS in both the early and late phases of 
the disease.6, 7 Prolonged-released (PR)-fampridine blocks voltage-gated potassium 
channels, thereby improving signal conduction in demyelinated nerve fibers.8, 9 Whereas 
beneficial effects of short-term treatment with PR-fampridine on maximal walking speed 
10-14 and additional functional outcomes 7, 13-15 (e.g. walking endurance) are well 
characterized in PwMS, little information exists regarding the long-term safety and 
efficacy of therapy with PR-fampridine. Open-label treatment over periods of 1 and 3 
years demonstrated good tolerability and persisting improvement in ambulatory 
function16 and fatigue.7 Positive effects of PR-fampridine on dynamic stability and self-
perceived walking ability were further demonstrated in a double-blind, placebo-
controlled study over a period of 24 weeks.15   
This study aims to expand upon the knowledge of the long-term effects of PR-
fampridine on walking function in PwMS. In contrast to prior long-term studies on PR-
fampridine, this study used annual drug holidays (open-label or placebo-controlled) to 
allow for accurate re-assessment of drug responsiveness, thus providing important 
information on changes in drug efficacy over time. Given the increasing number of 
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PwMS treated with PR-fampridine for MS-related walking dysfunction, there is a 
pressing need for a better understanding of the long-term effects of this therapy.  
 
Methods: 
Study population 
This extension trial was performed at the University Hospital Zurich, Switzerland, 
between 2013 and 2015. All participants enrolled in the trial had previously completed 
the core study (FAMPKIN, clinicaltrials.gov; NCT01576354). Detailed inclusion and 
exclusion criteria of the core study are reported elsewhere.14 No patients were excluded 
from the extension trial. In brief, participants diagnosed with relapsing-remitting, 
primary- or secondary-progressive MS with a clinically apparent walking impairment but 
able to cover a distance of at least 50 meters (with or without walking aids) in the 6-
Minute Walk Test (6MWT) were included. Of 55 patients completing the core study, 53 
(33 females; age: 50.3 ± 9.4 years; Table 1) were enrolled in the extension trial.  
 
Standard protocol approvals, registrations, and patient consents 
All experimental procedures of the study (NCT01576354) were performed according to 
the current guidelines of the Declaration of Helsinki and Good Clinical Practice and 
were approved by the Zurich cantonal ethics committee and the regulatory agency for 
medicines (Swissmedic). All participants provided informed, written consent to enter the 
extension trial.  
 
Study design 
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A screening visit (S) was performed at least 2 weeks after completion of the FAMPKIN 
core study. Based on earlier reports,11, 12, 14 a 14-day washout period is sufficient to 
avoid carry-over effects of PR-fampridine (Biogen, Cambridge, MA, USA). The first year 
of the extension trial was open-label, during which patients received 10mg PR-
fampridine twice daily for 11.5 months (figure 1A). Long-term treatment with PR-
fampridine was followed by a 14-day washout phase without treatment. Patients then 
received continuous, long-term treatment with PR-fampridine for a further 11.5 months 
before undergoing safety and efficacy assessments at the end of the second year in the 
form of a double-blind, placebo-controlled, cross-over component to obviate potential 
placebo effects. Analogous to the open-label drug holiday in the first year, the double-
blind treatment periods were limited to 14 days. At V5, patients were randomized 1:1 
into two groups (by the Zurich Cantonal Pharmacy), the first receiving placebo for 2 
weeks followed by 2 weeks of PR-fampridine with the order reversed for the second 
group. All experimenters and participants were blinded to the treatment allocation at the 
time of data assessment. Allocation concealment was removed after the last patient had 
completed the double blind study visit (V7).        
 
Study visits 
Safety assessments comprising laboratory safety measures (hematology, blood 
chemistry, urine analysis, creatinine clearance), measurement of vital signs, reporting of 
adverse events (AEs and SAEs) and assessment of changes in concomitant medication 
were performed at each study visit (figure 1B). Outcome measures relating to treatment 
efficacy consisted of the Timed 25-Foot Walk (T25FW), the 6MWT and the 12-item MS 
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Walking Scale (MSWS-12) questionnaire and were assessed at S, V2, V3 and V5 
(open-label) as well as at V6 and V7 (randomized, double-blind, placebo-controlled; 
figure 1B). The EDSS (Expanded Disability Status Scale) was assessed at S, V6 and 
V7. In addition to the MSWS-12, we also asked the patients to report on when they 
thought they were being treated with PR-fampridine or with placebo to investigate 
whether patients perceived fampridine-induced changes additional to ambulatory 
improvements.  
 
Statistical analysis 
Statistical analysis was performed with SPSS (V21, IBM Corp., USA). Three groups 
consisting of (1) all participants, (2) fampridine-responders and (3) non-responders were 
designated. Group classification was based on responder criteria defined in earlier 
publications 11, 12 and were applied based on the T25FW data of the core study: 
Fampridine-responders were participants achieving a faster walking speed in the 
T25FW for at least three of the four visits during the double-blind treatment periods 
compared to the maximum speed recorded during any of the five baseline visits. Chi 
square test and Fisher’s exact test were used to assess statistical significance of 
categorical variables. Statistical analysis of continuous demographic data was 
performed using two-tailed, unpaired t-tests. Changes in walking performance during 
treatment with PR-fampridine or placebo were assessed by two-tailed, paired t-tests or 
repeated measures one-way ANOVAs.  
 
Classification of evidence 
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The primary research question was to monitor the long-term effects of PR-fampridine on 
walking function in PwMS using three primary outcomes consisting of two quantitative 
clinical walking tests (T25FW, 6MWT) and the MSWS-12 questionnaire during open-
label and randomized, double-blind, controlled assessments (Class II evidence).  
 
Results: 
Fifty-three PwMS (24 relapsing remitting; 5 primary progressive; 24 secondary 
progressive) with an EDSS between 3.0 and 7.0 (mean: 5.3 ± 1.2) were included in the 
extension trial (Table 1). Forty-seven patients completed the first year (30 females; age: 
51.4 ± 9.3 years) and 36 patients (22 females; age: 52.0± 9.3 years) completed the 
second year of the trial. One patient was excluded from data analysis of V6 and V7 due 
to an elective surgical intervention between these visits. The demographics of the study 
population did not change over the 2 years of the extension trial (S, V3, V7; one-way 
ANOVA and two-tailed, unpaired t-test for age, disease duration, EDSS; Fisher’s exact 
test for gender). The demographics of the randomized groups (PR-fampridine first vs. 
placebo first group) during the double-blind treatment phase were not different in terms 
of age, duration and type of MS, disability (EDSS), gender and concomitant treatment 
(Table e-1). 
 
Long-term safety of PR-fampridine 
Forty-five of 53 PwMS showed at least one AE during the extension trial, resulting in a 
total of 129 AEs (Table e-2). The most common AEs were urinary tract infections, 
nasopharyngitis and nervous system disorders (Table e-3). The degree of severity was 
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mild for most AEs (71%), moderate for a subset (28%) and severe for a single AE 
(erysipelas). The relation of AEs to treatment was reported as unlikely for 23% and as 
possible for 77%. The number of AEs did not differ between the double-blind placebo 
and PR-fampridine treatment phases (Table e-2; p=0.4913, Chi square test). Fourteen 
of the 53 participants experienced at least one SAE with a total of 21 SAEs; eight of 
moderate severity and 13 graded severe. While the majority of SAEs were unrelated to 
the study medication, a causal connection to the study medication was deemed unlikely 
in five SAEs and possible in one. 
 
Long-term efficacy of PR-fampridine on walking function 
Treatment with PR-fampridine resulted in improvements in walking speed (T25FW; 
p=0.0274, one-way ANOVA) and endurance (6MWT; p=0.0002) across all patients and 
visits (figure 2A). Effects of PR-fampridine in both subgroups (PR-fampridine 
responders and non-responders) were similar to the total population in terms of 
magnitude of effect, but only the improvement in 6MWT in non-responders was 
statistically significant. Walking speed and endurance worsened significantly after 
discontinuation of study treatment for 2 weeks at the end of the first year (V2 vs. V3: -
11.5% in T25FW (95% confidence interval (CI) -4.9 to -18.0%); -10.7% in 6MWT (CI -
7.3 to -14.0%)). In both clinical gait tests, patients substantially recovered their walking 
capacity on re-initiating open-label treatment with PR-fampridine for another 11.5 
months (V3 vs. V5: +11.0% in T25FW (CI 3.5 to18.5%); +13.6 in 6MWT (CI 6.8 to 
20.4%)). This treatment effect also remained stable during the double-blind, placebo-
controlled assessment of drug efficacy: maximal walking speed improved by 13.1% (CI 
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4.1 to 22.1%) and walking endurance by 11.9% (CI 6.4 to 17.4%) during double-blind 
treatment with PR-fampridine compared to double-blind placebo treatment. Drug 
efficacy in the randomized group receiving PR-fampridine first was not different from 
that in the randomized group receiving placebo first during the double-blind treatment 
phase (p=0.2745 for T25FW, p=0.4339 for 6MWT, p=0.4313 for MSWS-12; unpaired, 
two-tailed t-test), indicating that the order of double-blind treatment did not influence 
drug efficacy. Overall walking capacity, as measured by the T25FW and 6MWT, 
worsened between the untreated baselines of the first year (figure 2A; S vs. V3), but 
remained constant between baselines at the end of the first and second year in our 
cohort (figure 2A; V3 vs. Plac). The averaged group performance while on PR-
fampridine (V2, V5) remained at the level of the untreated baseline (S). 
Paired, statistical analysis of drug efficacy during the open-label period (V2 vs. V3; 
figure 2B) and the double-blind controlled treatment phases (V6 vs. V7, figure 2B) 
revealed significant improvements during the open-label treatment in both functional 
tests and all sub-groups (except for non-responders in the T25FW; paired, two-tailed t-
test). Similarly, efficacy of PR-fampridine during the randomized, double-blind phase 
was highly significant for the total population, but only reached statistical significance in 
the subgroup of non-responders in the 6MWT (p=0.0154). 
   
Subjective long-term efficacy of PR-fampridine 
Self-estimated walking function was improved by PR-fampridine (figure 2A; MSWS-12; 
p=0.0002 for all participants, one-way ANOVA). Patients showed worsened self-
perception of ambulatory function when discontinuing the study medication for 2 weeks 
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(figure 2; V2 vs. V3: +6.2 points in MSWS-12 (CI 4.0 to 8.5 points); p<0.0001, paired, 
two-tailed t-test). The open-label effect of PR-fampridine on perceived walking function 
was highly significant for all subgroups (figure 2B). Drug efficacy during double-blind 
treatment was comparable to the open-label therapy in all participants (figure 2; V6 vs. 
V7: +7.0 points in MSWS-12 (CI -3.4 to -10.6 points); p=0.0003), but was not significant 
for the subgroups (figure 2B). 
Twenty-two of 31 patients correctly identified their allocation to the PR-fampridine arm 
(p=0.0196; Chi square test; five patients declined to report).  
 
Change in individual responsiveness to PR-fampridine over time 
To accurately monitor long-term efficacy of PR-fampridine, we tracked the individual 
drug response in 33 patients who completed the FAMPKIN core study and 2 years of 
the extension trial (figure 3). Demographic data of the 33 patients did not differ from the 
total populations of the core study (55 patients) or the extension trial (53 patients). 
Longitudinal analysis of drug efficacy revealed that, in many participants, the response 
to PR-fampridine changed over time (figure 3A, B). Whereas overall drug efficacy as 
measured by the T25FW and 6MWT was not different after 2 years of PR-fampridine 
treatment compared to short-term treatment in the core study (figure 3C; T25FW: 
+3.4%, p=0.3001; 6MWT: +3.9%, p=0.2136), self-perceived walking function 
significantly improved over time (figure 3C; MSWS-12: -5.1 points, p=0.0483). To further 
assess patients’ responsiveness to PR-fampridine, we analyzed the proportion of 
patients exceeding a specific threshold (T25FW and 6MWT: ≥ 10% improvement; 
MSWS-12: ≤ -6 points improvements) in the different tests during double-blind PR-
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fampridine treatment of the core study and the double-blind treatment period in the 
extension trial. The proportion of patients improving more than 10% in walking speed 
was significantly higher during long-term treatment with PR-fampridine compared to 
short-term treatment (figure 4; p=0.0169; Fisher’s exact test). Despite a similar trend in 
results, the proportion of patients responding in the extension trial versus the core study 
was not different in the 6MWT (short-term: 9/30 ≥ 10%; long-term: 15/30 ≥ 10%; 
p=0.1872) and the MSWS-12 (short-term: 10/33 ≤ -6 points; long-term: 12/33 ≤ -6 
points; p=0.7944). While a majority of patients with substantially improved gait function 
on PR-fampridine in the core study also showed a similar response after 2 years of 
long-term treatment (figure 3 and 4), more than one third of patients exhibiting no or 
poor initial improvements with PR-fampridine in the core study changed their response 
to the drug and demonstrated improved walking function when tested again after 2 
years (figure 4A). The trend towards increased responsiveness after long-term 
treatment was also observed for higher thresholds (i.e. 20% improvement in walking 
tests and 8 points in MSWS-12; figure 4B).  
Fampridine-induced changes in clinical walking tests were not correlated with the self-
assessed change in ambulatory performance in the double-blind core study (figure e-1; 
r=-0.2463, p=0.1742 for T25FW; r=0.0071, p=0.9705 for 6MWT). Conversely, in the 
double-blind phase of the extension trial, changes in MSWS-12 significantly correlated 
with clinical walking improvements (r=-0.4357, p=0.0127 for T25FW; r=-0.5851, 
p=0.0007 for 6MWT). 
 
Discussion: 
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The results of this extension trial emphasize the good tolerability of PR-fampridine in 
PwMS supporting previously published safety profiles of long-term PR-fampridine 
treatment.15-17 The proportion of patients experiencing AEs and SAEs was in line with 
previous reports.15, 16 The frequency of AEs was not different between double-blind 
treatment with PR-fampridine and placebo, indicating that PR-fampridine was likely not 
responsible for the AEs in PwMS treated with the drug. 
Our results demonstrate significant beneficial effects of long-term treatment with PR-
fampridine in all tested clinical outcomes over 2 years. To prevent bias due to patients 
with a good drug response remaining in the trial and participants with low 
responsiveness dropping out, we only included patients who completed the core study 
and both years of the extension trial, allowing comparison of short- and long-term drug 
effects. Using different thresholds of effect size in the T25FW, 6MWT and MSWS-12, 
we demonstrated that a considerable proportion of participants changed their response 
to PR-fampridine over two years of long-term treatment. The proportion of participants 
reaching an improvement threshold of 10% increased from one fifth (T25FW) and barely 
one third (6MWT) to one half of all patients (T25FW and 6MWT) after 2 years of PR-
fampridine treatment; a significant increase compared to short-term, double-blinded 
treatment. The majority of patients (80%) who showed greater than 10% improvement 
in the T25FW and 6MWT in the core study maintained a similar degree of 
responsiveness after long-term treatment. In contrast, 40% of patients initially falling 
short of the 10% improvement threshold in the T25FW and 6MWT during short-term 
treatment exhibited improvements ≥ 10% after 2 years. Increased responsiveness to 
PR-fampridine in these initial “poor responders”, combined with a potential decline of 
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drug efficacy in initial “good responders”, might explain the approximation of drug 
effects between responders and non-responders seen in earlier open-label long-term 
studies.16 The observed changes in drug response during long-term treatment suggest 
that drug efficacy should be re-evaluated regularly, in particular in those patients who 
demonstrate a poor response to PR-fampridine after initial assessment. Discussion 
relating to the mechanisms underlying the observed changes in responsiveness to the 
study drug over time must remain, for the moment, speculative. Since MS is a dynamic 
disease with de- and remyelination and axonal and neuronal death contributing to 
ongoing, structural alterations of the CNS grey and white matter during its course,18 
responsiveness to PR-fampridine may likewise change over time. As a potassium 
channel blocker, it may initially improve signal conduction in demyelinated axons only to 
be rendered ineffective once these axons undergo degeneration with the natural course 
of the disease. On the other hand, appearance of new, demyelinating lesions may result 
in clinical deterioration amenable to improvement, at least partially and transiently, with 
PR-fampridine treatment at that stage. Enhanced drug efficacy over time may also be 
the result of training effects made possible by the improved neurological state induced 
by PR-fampridine. Finally, the development of pharmacological tolerance may result in a 
decrease in efficacy during long-term treatment. Identification of patient characteristics 
(e.g. type of MS, concomitant treatment) associated with changes in responsiveness to 
PR-fampridine over time should be the focus of future, larger trials.  
The effect of PR-fampridine on self-perceived walking function reported here was higher 
than that reported by Huppert and colleagues15, perhaps due to their shorter treatment 
duration of 24 weeks. More than one third of our patients reached a threshold of 6 and 8 
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points improvements in the MSWS-12 questionnaire after 2 years of treatment. Both 
thresholds are associated with clinically meaningful improvement of walking function.15, 
19, 20 Poor correlations between self-perceived walking function and clinical 
improvements during short-term treatment with PR-fampridine as observed in the 
FAMPKIN core study are in line with previous results.19 Long-term treatment with PR-
fampridine, in contrast, revealed significant correlations between changes in subjective 
ambulatory function and walking speed and endurance, implying that patients 
developed a better appreciation of the effects induced by PR-fampridine over time. 
Significant effects of PR-fampridine on MSWS-12 are underlined by patients’ ability to 
correctly guess their allocation during double-blinded treatment arms.   
The current trial used a mixed study design combining open-label assessment of drug 
efficacy representative of clinical practice, as well as a double-blind, placebo-controlled 
analysis of treatment effects allowing the objective assessment of changes in 
ambulatory function and self-perceived walking performance as a result of PR-
fampridine. Similar drug efficacy during open-label and double-blind treatment phases 
emphasizes the objective and robust nature of the clinical walking tests used in this trial. 
Larger p-values for drug efficacy in the double-blind compared to the open-label phase 
are likely due to fewer patients completing the second year of the extension trial. 
Objective and reliable outcome measures of walking function are important in the 
translation to clinical practice, where patients are typically first assessed once before 
and again after 14 days of open-label treatment with PR-fampridine.21  
In contrast to previous long-term studies,15, 16 the present trial re-assessed drug efficacy 
at regular time intervals. The regular baseline assessments minimized the effect of 
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factors other than PR-fampridine which may influence walking function over time (e.g. 
disease progression, change in concomitant treatment), allowing close and accurate 
monitoring of drug responsiveness in individual participants over more than 2 years.  
A key constraint of the current trial is the limited number of patients, which is due to the 
intensity and logistics of such a comprehensive study design required to accurately 
track patients’ individual responsiveness over time. Further long-term data of PR-
fampridine in PwMS are needed to confirm these results. A second limitation is that 
double-blind, long-term effects of PR-fampridine were only assessed in half of the 
participants, i.e. those receiving PR-fampridine at V5. The other half was randomized to 
be treated with placebo first before re-initiating treatment with PR-fampridine at V6. 
Treatment effects in both groups were, however, not different in any of the clinical 
walking tests.  
This study demonstrates the good tolerability and significant persisting effects of long-
term treatment with PR-fampridine on ambulatory performance in PwMS over a period 
of more than 2 years. PR-fampridine-induced walking improvements are perceived by 
most patients. Against a background of persisting improvements of walking function 
across all patients, longitudinal assessment of drug efficacy revealed remarkable 
changes in responsiveness to PR-fampridine in some patients. In particular, those 
patients who showed a moderate to poor response in terms of walking improvement 
under PR-fampridine at initial assessment were liable to improve their responsiveness 
to the drug over time, thus highlighting the necessity to regularly re-assess the efficacy 
of PR-fampridine on ambulatory function in PwMS. Persisting drug efficacy, combined 
with the fact that PR-fampridine has also demonstrated beneficial effects in chronic 
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progressive MS 14, 16, where alternative treatment options to improve walking function 
are virtually absent, confirm PR-fampridine as an important option in symptomatic, long-
term treatment for gait-impaired PwMS.  
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Figure legends 
Figure 1 Experimental study design and schedule of assessments.  
Figure 1. (A) Study design of the extension trial. The first 2 years of the extension trial 
were performed with an open-label format (S-V5). Thereafter, gait function was 
examined in two randomized, double-blind treatment periods of 2 weeks each, during 
which patients took either PR-fampridine or placebo in a cross-over component (V6, 
V7). (B) Schedule of study assessments. Abbreviations: EDSS: Expanded Disability 
Status Scale; T25FW: Timed 25-Foot Walk; 6MWT: 6-Minute Walk Test; MSWS12: 
Multiple Sclerosis Walking Scale (12-items); S: screening; V: visits. 
 
Figure 2 Walking performance and self-perceived ambulatory function at different 
time points during the extension trial. 
Figure 2. (A) Data is displayed relative to baseline performance at the screening visit 
(S). Assessments at V2 (long-term PR-fampridine), V3 (drug washout) and V5 (long-
term PR-fampridine) were performed in an open-label study design. Measurements at 
V6 and V7 were performed under randomized, double-blind conditions. Data for the 
randomized cross-over visits V6 and V7 was allocated according to the respective 
treatment (placebo (Plac); PR-fampridine (Famp)). Results are shown for all participants 
(black), for PR-fampridine responders (red) and for non-responders (blue). Data points 
represent group mean values ± standard error of the mean (s.e.m). P-values indicate 
statistical significance (one-way ANOVA) of respective data curves. (B) P-values 
reflecting the effect of PR-fampridine on different clinical tests during the open-label 
treatment (upper table, V2 vs. V3) and during the randomized, double-blind, placebo-
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controlled treatment phase (lower table, V6 vs. V7) for all patients (all), for PR-
fampridine-responders (responders), and for non-responders. Only patients completing 
all treatment phases (V2 and V3; V6 and V7) were included in the analysis (two-tailed, 
paired t-test) Abbreviations: T25FW: Timed 25-Foot Walk; 6MWT: 6-Minute Walk Test; 
MSWS12: Multiple Sclerosis Walking Scale (12-items); V: visits. 
 
Figure 3 Individual drug responsiveness during short- and long-term treatment 
with PR-fampridine.   
Figure 3. (A) Subject-specific comparison of PR-fampridine effects during short-term 
double-blind treatment in the core study and long-term double-blind treatment in the 
extension trial. Data points represent treatment effects under PR-fampridine relative to 
placebo for single PR-fampridine responders (left) and non-responders (right) during the 
core study and the extension trial (T25FW: responders (n=10), non-responders (n=15); 
6MWT: responders (n=10), non-responders (n=13); MSWS-12: responders (n=11), non-
responders (n=15)). (B) Changes in drug responsiveness of single participants between 
the core study and the extension trial in the T25FW, 6MWT and MSWS-12. Fields are 
arranged according to the magnitude of change in responsiveness for each outcome 
(red: improved responsiveness after long-term compared to short-term treatment; blue: 
reduced responsiveness after long-term compared to short-term treatment). Patient ID 
number is indicated on the left side of each outcome (T25FW: n=32; 6MWT: n=30; 
MSWS-12: n=33; same for (C)). (C) Treatment efficacy during short-term double-blind 
treatment in the core study (white bars) and long-term double-blind treatment in the 
extension trial (black bars) over all patients. Abbreviations: T25FW: Timed 25-Foot Walk 
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Test; 6MWT: 6-Minute Walk Test; MSWS-12: 12-item Multiple Sclerosis Walking Scale; 
Resp: PR-fampridine responders, Non-Resp: non-responders, *: p<0.05. 
 
Figure 4 Changes in drug responsiveness over time 
Figure 4. (A) Proportion of patients improving in walking speed (+10%), endurance 
(+10%) and self-perceived walking ability (-6 points) during the double-blind, controlled 
treatment phases in the FAMPKIN core study and the extension trial. The group of 
patients improving more than 10% in clinical walking tests or more than 6 points in the 
MSWS-12 is indicated in blue (pie chart), whereas patients showing decreased 
responsiveness to PR-fampridine are displayed in red. (B) As in figure 4A, but using 
higher threshold values (walking speed and endurance: 20%; self-perceived walking 
ability: 8 points). Only patients who completed the second year of the extension trial 
were included in the analysis (T25FW: n=32, 6MWT: n=30, MSWS-12: n=33). 
Abbreviations: T25FW: Timed 25-Foot Walk Test; 6MWT: 6-Minute Walk Test; MSWS-
12: 12-item Multiple Sclerosis Walking Scale; pts: points. 
 
Table 1 Demographic data of the study population at screening.   
Table 1. Abbreviations: DMF: dimethyl fumarate; EDSS: Expanded Disability Status 
Scale; PPMS: primary progressive MS; RRMS: relapsing-remitting MS; SPMS: 
secondary progressive MS; SD: standard deviation; y: years. 
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Table 1 
 
  screening 1st year of extension 2nd year of extension 
  Included (n=53) Completed (n=47) Discontinued (n=6) Completed (n=36) Discontinued (n=11) 
Age (y), mean ± SD   50.3 ± 9.4 51.4 ± 9.3 48.4 ± 8.0 52.0 ± 9.3 50.3 ± 9.4 
Gender, number (%) Male 20 (38) 17 (36) 3 (50) 14 (39) 3 (27) 
Female 33 (62) 30 (64) 3 (50) 22 (61) 8 (73) 
Type of MS, number (%) RRMS 24 (45) 20 (42) 3 (50) 16 (44) 4 (36) 
PPMS 5 (10) 5 (11) 0 4 (11) 1 (9) 
SPMS 24 (45) 22 (47) 3 (50) (16 (44) (6 (55) 
Disease duration (y) from 
diagnosis, mean ± SD 
 12.7 ± 7.3 13.7 ± 7.5 12.3 ± 5.0 15.4 ± 8.1 10.9 ± 5.4 
EDSS, mean ± SD No treatment 5.3 ± 1.2  6.3 ± 0.3  5.7 ± 1.1 
Placebo    5.1 ± 1.3  
PR-fampridine    5.0 ± 1.3  
Concomitant MS 
treatment, number (%) 
Total 29 (55) 25 (53) 4 (67) 17 (47) 7 (64) 
Interferon 7 (13) 5 (11) 1 (17) 3 (8) 2 (18) 
Natalizumab 17 (32) 14 (30) 2 (33) 6(17) 4 (36) 
Fingolimod 5 (9) 5 (11) 1 (17) 4 (11) 1 (9) 
DMF 0 1 (2) 0 4 (11) 0 
 
